|
1
|
Di Sandro S, Danieli M, Ferla F, Lauterio
A, Carlis RD, Benuzzi L, Buscemi V, Pezzoli I and Carlis LD: The
current role of laparoscopic resection for HCC: A systematic review
of past ten years. Transl Gastroenterol Hepatol. 3:682018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aghemo A: Update on HCC management and
review of the new EASL guidelines. Gastroenterol Hepatol (N Y).
14:384–386. 2018.PubMed/NCBI
|
|
3
|
Bolondi L, Piscaglia F, Camaggi V, Grazi
GL and Cavallari A: Review article: Liver transplantation for HCC.
Treatment options on the waiting list. Aliment Pharmacol Ther. 17
(Suppl 2):S145–S150. 2003. View Article : Google Scholar
|
|
4
|
Liu CY, Chen KF and Chen PJ: Treatment of
liver cancer. Cold Spring Harb Perspect Med. 5:a0215352015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marengo A, Rosso C and Bugianesi E: Liver
cancer: Connections with obesity, fatty liver, and cirrhosis. Annu
Rev Med. 67:103–117. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mohr AM and Mott JL: Overview of microRNA
biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Annu Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gentilin E, Degli Uberti E and Zatelli MC:
Strategies to use microRNAs as therapeutic targets. Best Pract Res
Clin Endocrinol Metab. 30:629–639. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mizuguchi Y, Takizawa T, Yoshida H and
Uchida E: Dysregulated miRNA in progression of hepatocellular
carcinoma: A systematic review. Hepatol Res. 46:391–406. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qiu H, Zhang G, Song B and Jia J:
MicroRNA-548b inhibits proliferation and invasion of hepatocellular
carcinoma cells by directly targeting specificity protein 1. Exp
Ther Med. 18:2332–2340. 2019.PubMed/NCBI
|
|
13
|
Okumura T, Kojima H, Miwa T, Sekine S,
Hashimoto I, Hojo S, Nagata T and Shimada Y: The expression of
microRNA 574-3p as a predictor of postoperative outcome in patients
with esophageal squamous cell carcinoma. World J Surg Oncol.
14:2282016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chiyomaru T, Yamamura S, Fukuhara S,
Hidaka H, Majid S, Saini S, Arora S, Deng G, Shahryari V, Chang I,
et al: Genistein up-regulates tumor suppressor microRNA-574-3p in
prostate cancer. PLoS One. 8:e589292013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang M, Zhang R, Zhang S, Xu R and Yang Q:
MicroRNA-574-3p regulates epithelial mesenchymal transition and
cisplatin resistance via targeting ZEB1 in human gastric carcinoma
cells. Gene. 700:110–119. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ujihira T, Ikeda K, Suzuki T, Yamaga R,
Sato W, Horie-Inoue K, Shigekawa T, Osaki A, Saeki T, Okamoto K, et
al: MicroRNA-574-3p, identified by microRNA library-based
functional screening, modulates tamoxifen response in breast
cancer. Sci Rep. 5:76412015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Krishnan P, Ghosh S, Wang B, Li D,
Narasimhan A, Berendt R, Graham K, Mackey JR, Kovalchuk O and
Damaraju S: Next generation sequencing profiling identifies
miR-574-3p and miR-660-5p as potential novel prognostic markers for
breast cancer. BMC Genomics. 16:7352015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shen X, Xue Y, Cong H, Wang X and Ju S:
Dysregulation of serum microRNA-574-3p and its clinical
significance in hepatocellular carcinoma. Ann Clin Biochem.
55:478–484. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gui J, Tian Y, Wen X, Zhang W, Zhang P,
Gao J, Run W, Tian L, Jia X and Gao Y: Serum microRNA
characterization identifies miR-885-5p as a potential marker for
detecting liver pathologies. Clin Sci (Lond). 120:183–193. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tortorella MD, Malfait F, Barve RA, Shieh
HS and Malfait AM: A review of the ADAMTS family, pharmaceutical
targets of the future. Curr Pharm Des. 15:2359–2374. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Reiss K and Saftig P: The ‘a disintegrin
and metalloprotease’ (ADAM) family of sheddases: Physiological and
cellular functions. Semin Cell Dev Biol. 20:126–137. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Duffy MJ, McKiernan E, O'Donovan N and
McGowan PM: Role of ADAMs in cancer formation and progression. Clin
Cancer Res. 15:1140–1144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mitsui Y, Mochizuki S, Kodama T, Shimoda
M, Ohtsuka T, Shiomi T, Chijiiwa M, Ikeda T, Kitajima M and Okada
Y: ADAM28 is overexpressed in human breast carcinomas: Implications
for carcinoma cell proliferation through cleavage of insulin-like
growth factor binding protein-3. Cancer Res. 66:9913–9920. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mochizuki S, Shimoda M, Abe H, Miyamae Y,
Kuramoto J, Aramaki-Hattori N, Ishii K, Ueno H, Miyakoshi A, Kojoh
K and Okada Y: Selective inhibition of ADAM28 suppresses lung
carcinoma cell growth and metastasis. Mol Cancer Ther.
17:2427–2438. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang JM, Wang CC, Zhang GC, Jiang Q, Yang
SM, Fu HX, Wang QM, Zhu XL, Zhu HH, Jiang H, et al: ADAM28 promotes
tumor growth and dissemination of acute myeloid leukemia through
IGFBP-3 degradation and IGF-I-induced cell proliferation. Cancer
Lett. 442:193–201. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang J, Li H, Wang Y, Wang L, Yan X, Zhang
D, Ma X, Du Y, Liu X and Yang Y: MicroRNA-552 enhances metastatic
capacity of colorectal cancer cells by targeting a disintegrin and
metalloprotease 28. Oncotarget. 7:70194–70210. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Grossi I, Arici B, Portolani N, De Petro G
and Salvi A: Clinical and biological significance of miR-23b and
miR-193a in human hepatocellular carcinoma. Oncotarget.
8:6955–6969. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang X and Jia Z: Construction of
HCC-targeting artificial miRNAs using natural miRNA precursors. Exp
Ther Med. 6:209–215. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lou W, Liu J, Ding B, Chen D, Xu L, Ding
J, Jiang D, Zhou L, Zheng S and Fan W: Identification of potential
miRNA-mRNA regulatory network contributing to pathogenesis of
HBV-related HCC. J Transl Med. 17:72019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu H, Liu X, Zhou J, Chen X and Zhao J:
miR-574-3p acts as a tumor promoter in osteosarcoma by targeting
SMAD4 signaling pathway. Oncol Lett. 12:5247–5253. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zheng J, Zhou Y, Li XJ and Hu JM:
miR-574-3p exerts as a tumor suppressor in ovarian cancer through
inhibiting MMP3 expression. Eur Rev Med Pharmacol Sci.
23:6839–6848. 2019.PubMed/NCBI
|
|
33
|
Zhang P, Zhu J, Zheng Y, Zhang H, Sun H
and Gao S: miRNA-574-3p inhibits metastasis and chemoresistance of
epithelial ovarian cancer (EOC) by negatively regulating epidermal
growth factor receptor (EGFR). Am J Transl Res. 11:4151–4165.
2019.PubMed/NCBI
|
|
34
|
Summerer I, Unger K, Braselmann H,
Schuettrumpf L, Maihoefer C, Baumeister P, Kirchner T, Niyazi M,
Sage E, Specht HM, et al: Circulating microRNAs as prognostic
therapy biomarkers in head and neck cancer patients. Br J Cancer.
113:76–82. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ishikawa K, Ishikawa A, Shoji Y and Imai
T: A genotoxic stress-responsive miRNA, miR-574-3p, delays cell
growth by suppressing the enhancer of rudimentary homolog gene in
vitro. Int J Mol Sci. 15:2971–2990. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Grossi I, Salvi A, Baiocchi G, Portolani N
and De Petro G: Functional role of microRNA-23b-3p in cancer
biology. Microrna. 7:156–166. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li H, Guo X, Li Q, Ran P, Xiang X, Yuan Y,
Dong T, Zhu B, Wang L, Li F, et al: Long non-coding RNA 1308
promotes cell invasion by regulating the miR-124/ADAM 15 axis in
non-small-cell lung cancer cells. Cancer Manag Res. 10:6599–6609.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang X, Cui Y, Yang F, Sun C and Gao X:
MicroRNA302a suppresses cell proliferation, migration and invasion
in osteosarcoma by targeting ADAM9. Mol Med Rep. 16:3565–3572.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ji T, Zhang X and Li W: MicroRNA543
inhibits proliferation, invasion and induces apoptosis of
glioblastoma cells by directly targeting ADAM9. Mol Med Rep.
16:6419–6427. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hua Y, Liang C, Miao C, Wang S, Su S, Shao
P, Liu B, Bao M, Zhu J, Xu A, et al: MicroRNA-126 inhibits
proliferation and metastasis in prostate cancer via regulation of
ADAM9. Oncol Lett. 15:9051–9060. 2018.PubMed/NCBI
|
|
41
|
Liu Q, Jiang J, Fu Y, Liu T, Yu Y and
Zhang X: miR-129-5p functions as a tumor suppressor in gastric
cancer progression through targeting ADAM9. Biomed Pharmacother.
105:420–427. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li LX, Lam IH, Liang FF, Yi SP, Ye LF,
Wang JT, Guo WW and Xu M: miR-198 affects the proliferation and
apoptosis of colorectal cancer through regulation of
ADAM28/JAK-STAT signaling pathway. Eur Rev Med Pharmacol Sci.
23:1487–1493. 2019.PubMed/NCBI
|
|
43
|
Ge X, Cui H, Zhou Y, Yin D, Feng Y, Xin Q,
Xu X, Liu W, Liu S and Zhang Q: miR-320a modulates cell growth and
chemosensitivity via regulating ADAM10 in gastric cancer. Mol Med
Rep. 16:9664–9670. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li J, Lu M, Jin J, Lu X, Xu T and Jin S:
miR-449a suppresses tamoxifen resistance in human breast cancer
cells by targeting ADAM22. Cell Physiol Biochem. 50:136–149. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
van Kampen JGM, van Hooij O, Jansen CF,
Smit FP, van Noort PI, Schultz I, Schaapveld RQJ, Schalken JA and
Verhaegh GW: miRNA-520f reverses epithelial-to-mesenchymal
transition by targeting ADAM9 and TGFBR2. Cancer Res. 77:2008–2017.
2017. View Article : Google Scholar : PubMed/NCBI
|
